The Department of Justice is looking into Medicaid pricing.
Switzerland is pushing Roche to lower its prices on Perjeta
The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.
Diet and exercise can help some type-2 diabetes patients save around $500 in medical expenses every year.
UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.
Britain's National Institute for Health and Care Excellence has followed through on its Kadcyla objections and has said Roche's breast cancer drug will remain off the National Health Services formulary because it is too expensive.
Medibid users auction up care in exchange for a low price.
Health insurer WellPoint found patients chose lower-priced MRIs when shown how much locations charged for the very same procedure, but the motivation is murky.
The decades-old drug is winning prescriptions through marketing, but has a free-pass when it comes to clinical trial data.
The PBM dropped 25 more drugs from its formulary.
The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
Prices for some generics are rising, thanks to limited competition.
UnitedHealthcare finds drug costs more than doubled.
French lawmakers have the chance to vote for off-label use of Avastin, potentially eating into the turf of higher-priced Lucentis.
The Italian Medicines Agency is guiding patients away from Roche's costlier AMD-indicated Lucentis.
The Oregon Health Plan wants to keep hep. C medications Sovaldi and Olysio off its list of covered treatments.
Drug quality problems and shortages are behind the shift that will affect antibiotics, painkillers and vitamins.
An EY report finds that pharma is not only failing to give payers the right type of drug data, but that industry has a lot of trust-building to do before they will accept it.
Physicians tell Leerink most of their patients are receiving the drug. Rejections tend to be over off-label use.
The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
A report indicates that Sovaldi's high price may hurt health-insurance investors.
The professional association says it's necessary, because high prices do not indicate impact.
The UK's National Institute for Health and Care Excellence says it bounced Bayer's drug for failing to compare itself to current treatments, and Sanofi's over cost.
Insurers and state agencies are wondering if and how they can cover the $84,000 hep. C drug.
The UK watchdog wants to know what's behind the rare-disease drug's high price.
Germany's price transparency requirement has the industry worried other markets will demand lower prices.
The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.
The third Pharmacy Benefit Management Institute specialty medication survey expects specialty medications, which average around $3,000 per month per patient, will account for 50% of the drug spend within four or five years.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.